However, a Phase II clinical trial showed no clinical benefit of combining TMZ with the MGMT inhibitor O6-benzylguanine (O6BG) in recurrent TMZ-resistant GBM [18], suggesting that additional mechanisms may account for GBM resistance to TMZ chemotherapy. Here, MGMT is linked to glioblastoma.